[EN] DUAL ACTION NITRIC OXIDE DONORS AND THEIR USE AS ANTIMICROBIAL AGENTS<br/>[FR] DONNEURS D'OXYDE NITRIQUE À DOUBLE ACTION ET LEUR UTILISATION COMME AGENTS ANTIMICROBIENS
申请人:NEWSOUTH INNOVATIONS PTY LTD
公开号:WO2014071457A1
公开(公告)日:2014-05-15
The present invention relates generally to conjugates comprising a nitric oxide donor and an acyl homoserine lactone, fimbrolide, fimbrolide derivative, dihydropyrrolone or indole, and to the use of such conjugates as antimicrobial agents.
The Secondary Amine/Nitric Oxide Complex Ion R<sub>2</sub>N[N(O)NO]<sup>-</sup> as Nucleophile and Leaving Group in S<sub>N</sub>Ar Reactions
作者:Joseph E. Saavedra、Aloka Srinivasan、Challice L. Bonifant、Jingxi Chu、Anna P. Shanklin、Judith L. Flippen-Anderson、William G. Rice、Jim A. Turpin、Keith M. Davies、Larry K. Keefer
DOI:10.1021/jo0016529
日期:2001.5.1
the cis arrangement of the oxygens were confirmed by X-ray crystallography. Displacement by various nucleophiles showed R(2)N[N(O)NO](-) to be a reasonably good leaving group, with rate constants for displacement by hydroxide, methoxide, and isopropylamine that were between those of chloride and fluoride in the S(N)Ar reactions we surveyed. The Meisenheimer intermediate could be spectrally observed. These
Design, Synthesis, and Evaluation of Fimbrolide–Nitric Oxide Donor Hybrids as Antimicrobial Agents
作者:Samuel K. Kutty、Nicolas Barraud、Amy Pham、George Iskander、Scott A. Rice、David StC. Black、Naresh Kumar
DOI:10.1021/jm400951f
日期:2013.12.12
in bacteria controlling biofilm formation and virulence factor. Nitric oxide (NO) at sublethal concentration has also been reported to induce dispersal of bacterialbiofilms and increase their susceptibility toward standard biocides and antibiotics. Therefore, the combination of QS inhibitors and NO donors has the potential to control the development of biofilm and promote their dispersion via a nonbactericidal
[EN] ANGIOTENSIN II RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE L'ANGIOTENSINE II
申请人:MERCK & CO INC
公开号:WO2009094242A1
公开(公告)日:2009-07-30
A compound having the structure (I) wherein R is an angiotensin receptor antagonist active group, Y is selected from the group consisting of (II), and 2) -C(R1H)OC(O)X((CR12R13)-(CHR10)m-(CH2)n-Zp-(CH2)q-(CHR11)r-(CR16R17))-R5; Z is O- or (CR14R15)-; m, n, p, q, and r are independently selected from the group consisting of 0 and 1; X is O- or (CR18R19)-; R1 is selected from the group consisting of hydrogen, C1-4 alkyl, aryl and C1-4 alkylaryl; R5 is -O-N=N(O)-NR3R4; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.
O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
申请人:Government of the USA, the Secretary Department of Health and Human Services
公开号:US20030147845A1
公开(公告)日:2003-08-07
Diazeniumdiolates, wherein the N
1
position is substituted by an inorganic or organic moiety and the O
2
-oxygen is bound to a substituted or unsubstituted aromatic group, are provided. Also provided are O
2
-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O
2
-glycosylated diazeniumdiolates) and O
2
-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates). The O
2
-aryl diazeniumdiolates are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions and generate nitric oxide in basic or nucleophilic environments or microenvironments. Also provided are compositions, including pharmaceutical compositions, comprising such compounds and methods of using such compounds.